Wave Life Sciences (WVE) EBIT Margin (2015 - 2026)
Wave Life Sciences' (WVE) quarterly EBIT Margin came in at 3248.33% in Q2 2026, down 264183.0% YoY from N/an in Q2 2025, and down 3869.44% on a QoQ basis from 81.83% in Q1 2026.
Powered by 
Analysis
Wave Life Sciences (WVE) EBIT Margin (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of EBIT Margin data on file, last reported at 3248.33% in Q2 2026.
- Quarterly EBIT Margin fell 264183.0% year-over-year to 3248.33% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 373.2% (down 8678.0% YoY) and the FY2025 annual result came in at 504.09%, down 40215.0% from the prior year.
- EBIT Margin eased to 3248.33% in Q2 2026, from 81.83% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 9.03% in Q3 2023 to a low of 13648.77% in Q3 2022.
- A 5-year average of 2565.21% and a median of 408.83% in 2025 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin sank 1362789 bps — and 2023, when it surged 1365780 bps.
- Tracing WVE's EBIT Margin over 5 years: stood at 3515.98% in 2022, then jumped by 98 bps to 64.3% in 2023, then slumped by 176 bps to 177.72% in 2024, then plunged by 241 bps to 606.49% in 2025, then plunged by 436 bps to 3248.33% in 2026.
- The last three EBIT Margin figures came in at 3248.33% (Q2 2026), 81.83% (Q1 2026), and 606.49% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - | -3,248.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,248.33% |
| Mar 31, 2026 | -81.83% |
| Dec 31, 2025 | -327.44% |
| Sep 30, 2025 | -740.71% |
| Jun 30, 2025 | -606.49% |
| Mar 31, 2025 | -542.82% |
| Dec 31, 2024 | 27.42% |
| Sep 30, 2024 | -832.66% |
| Jun 30, 2024 | -177.72% |
| Mar 31, 2024 | -274.83% |
| Dec 31, 2023 | -64.30% |
| Sep 30, 2023 | 9.03% |
| Jun 30, 2023 | -106.18% |
| Mar 31, 2023 | -234.24% |
| Dec 31, 2022 | -3,515.98% |
| Sep 30, 2022 | -13,648.77% |
| Jun 30, 2022 | -11,243.73% |
| Mar 31, 2022 | -2,176.80% |
| Dec 31, 2021 | -2,045.89% |
| Sep 30, 2021 | -20.89% |